GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
GO:004860813 | Cervix | HSIL_HPV | reproductive structure development | 32/737 | 424/18723 | 3.52e-04 | 5.54e-03 | 32 |
GO:006145814 | Cervix | HSIL_HPV | reproductive system development | 32/737 | 427/18723 | 3.98e-04 | 6.14e-03 | 32 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
GO:00988132 | Oral cavity | OSCC | nuclear chromosome segregation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:006145817 | Oral cavity | OSCC | reproductive system development | 217/7305 | 427/18723 | 3.75e-07 | 5.63e-06 | 217 |
GO:004860816 | Oral cavity | OSCC | reproductive structure development | 214/7305 | 424/18723 | 8.58e-07 | 1.18e-05 | 214 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYCP2 | SNV | Missense_Mutation | novel | c.4175N>T | p.Ala1392Val | p.A1392V | Q9BX26 | protein_coding | tolerated(0.22) | benign(0.025) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCP2 | SNV | Missense_Mutation | novel | c.706N>A | p.Ala236Thr | p.A236T | Q9BX26 | protein_coding | deleterious(0) | possibly_damaging(0.63) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCP2 | SNV | Missense_Mutation | novel | c.2919G>T | p.Lys973Asn | p.K973N | Q9BX26 | protein_coding | tolerated(0.05) | possibly_damaging(0.812) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCP2 | SNV | Missense_Mutation | rs142565688 | c.2032G>A | p.Asp678Asn | p.D678N | Q9BX26 | protein_coding | tolerated(0.48) | benign(0.054) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCP2 | SNV | Missense_Mutation | novel | c.1734T>G | p.Phe578Leu | p.F578L | Q9BX26 | protein_coding | tolerated(0.85) | benign(0.006) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCP2 | SNV | Missense_Mutation | | c.4130G>A | p.Arg1377Gln | p.R1377Q | Q9BX26 | protein_coding | tolerated(0.17) | benign(0.035) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SYCP2 | SNV | Missense_Mutation | novel | c.2573T>G | p.Phe858Cys | p.F858C | Q9BX26 | protein_coding | deleterious(0.04) | possibly_damaging(0.799) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SYCP2 | SNV | Missense_Mutation | novel | c.1385G>T | p.Arg462Ile | p.R462I | Q9BX26 | protein_coding | tolerated(0.33) | benign(0.012) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SYCP2 | SNV | Missense_Mutation | | c.2894N>C | p.Asp965Ala | p.D965A | Q9BX26 | protein_coding | deleterious(0) | benign(0.158) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SYCP2 | SNV | Missense_Mutation | rs142565688 | c.2032N>A | p.Asp678Asn | p.D678N | Q9BX26 | protein_coding | tolerated(0.48) | benign(0.054) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |